Skip to main content
. 2021 Dec 21;326(23):2395–2404. doi: 10.1001/jama.2021.21222

Figure 2. Primary Outcome in a Study of the Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Atrial Fibrillation.

Figure 2.

Adjusted cumulative incidence of major ischemic (ischemic stroke or systemic embolism) or hemorrhagic (hemorrhagic stroke, other intracranial bleeding, fatal extracranial bleeding) events. The median (IQR) follow-up time was 5.8 (2.1-13.2) months. Adjusted with inverse probability of treatment weighting; the variables used in the adjustment are shown in eTable 5 in the Supplement.